A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

Abroad (travel likely)RecruitingPHASE4

Conditions

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) · Human Papillomavirus (HPV) Infections · High-risk HPV · HPV-16/ 18

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Gynaecology Unit, Bellvitge University Hospital (HUB), L'Hospitalet de Llobregat, Catalonia, Spain
Contact: Study coordinator (Marta López Querol, SC) · mlopezq@idibell.cat · +34 932607123
Contact: Study coordinator (Miquel Àngel Pabon Ribas, PI) · mpavon@iconcologia.net · +34 932607123

Study leads

Miquel Àngel Pavón Ribas, PhD
Principal Investigator
Cancer Epidemiology Research Program (PREC), Catalan Institute of Oncology (ICO-Hospitalet)/Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
Francesc Xavier Bosch José, PhD - MD
Principal Investigator
Cancer Epidemiology Research Program (PREC), Catalan Institute of Oncology (ICO-Hospitalet)/Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.

View source on ClinicalTrials.gov